Compare LXEO & PPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LXEO | PPHC |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.7M | 295.2M |
| IPO Year | 2023 | 2025 |
| Metric | LXEO | PPHC |
|---|---|---|
| Price | $3.19 | $10.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $20.67 | $17.00 |
| AVG Volume (30 Days) | ★ 1.1M | 104.3K |
| Earning Date | 11-16-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 3.44% |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $654,000.00 | ★ $186,541,000.00 |
| Revenue This Year | N/A | $15.33 |
| Revenue Next Year | N/A | $14.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.72 |
| 52 Week Low | $2.55 | $7.01 |
| 52 Week High | $10.99 | $15.15 |
| Indicator | LXEO | PPHC |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 45.14 |
| Support Level | $2.72 | $9.72 |
| Resistance Level | $3.56 | $11.76 |
| Average True Range (ATR) | 0.38 | 0.91 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 25.62 | 14.24 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations. Its business comprises of three reporting segments - Government Relations Consulting, Corporate Communications & Public Affairs Consulting and Compliance and Insights Services.